It's Showtime for Pacira Pharmaceuticals
Pacira Pharmaceuticals (NAS: PCRX) is expected to report Q4 earnings on March 7. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pacira Pharmaceuticals's revenues will grow 132.3% and EPS will remain in the red.
The average estimate for revenue is $9.8 million. On the bottom line, the average EPS estimate is -$0.42.
Last quarter, Pacira Pharmaceuticals tallied revenue of $8.5 million. GAAP reported sales were much higher than the prior-year quarter's $4.0 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.49. GAAP EPS were -$0.49 for Q3 compared to -$0.55 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was -9.4%, much worse than the prior-year quarter. Operating margin was -185.1%, much better than the prior-year quarter. Net margin was -185.5%, much better than the prior-year quarter.
The full year's average estimate for revenue is $38.4 million. The average EPS estimate is -$1.63.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 20 members out of 30 rating the stock outperform, and 10 members rating it underperform. Among 11 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), six give Pacira Pharmaceuticals a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $21.20.
- Add Pacira Pharmaceuticals to My Watchlist.
The article It's Showtime for Pacira Pharmaceuticals originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.